Oncoscience | RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.